{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(5)"],"submitter":["Shen L"],"pubmed_abstract":["<h4>Objective</h4>A combination of glucocorticoids with mycophenolate is recommended by current guidelines to boost response to Graves' orbitopathy (GO) therapy. This study was designed to evaluate the therapeutic effects and safety of methotrexate (MTX) plus reduced (3.0 g) or full-dose (4.5 g) i.v. methylprednisolone (MP) vs full-dose i.v. MP alone.<h4>Design and methods</h4>This was a prospective, randomized, observer-masked, single-center clinical trial conducted in a tertiary clinical center. Ninety-seven patients with active moderate-to-severe GO were screened and 90 patients underwent randomization between April 2018 and Oct 2019. All patients completed 12 weeks of treatment and received clinical assessment. The patients received either MP 4.5 g only, MP 4.5 g plus oral MTX, or MP 3"],"journal":["European thyroid journal"],"pagination":["e220017"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9422237"],"repository":["biostudies-literature"],"pubmed_title":["Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy."],"pmcid":["PMC9422237"],"pubmed_authors":["Shen L","Ye L","Jiao Q","Wang S","Wang W","Zhu W","Zhou Y","Ning G"],"additional_accession":[]},"is_claimable":false,"name":"Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy.","description":"<h4>Objective</h4>A combination of glucocorticoids with mycophenolate is recommended by current guidelines to boost response to Graves' orbitopathy (GO) therapy. This study was designed to evaluate the therapeutic effects and safety of methotrexate (MTX) plus reduced (3.0 g) or full-dose (4.5 g) i.v. methylprednisolone (MP) vs full-dose i.v. MP alone.<h4>Design and methods</h4>This was a prospective, randomized, observer-masked, single-center clinical trial conducted in a tertiary clinical center. Ninety-seven patients with active moderate-to-severe GO were screened and 90 patients underwent randomization between April 2018 and Oct 2019. All patients completed 12 weeks of treatment and received clinical assessment. The patients received either MP 4.5 g only, MP 4.5 g plus oral MTX, or MP 3","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-22T07:02:41.458Z","creation":"2025-04-05T21:58:08.598Z"},"accession":"S-EPMC9422237","cross_references":{"pubmed":["35900774"],"doi":["10.1530/ETJ-22-0017"]}}